FDA accepts supplemental biologics license application for Roche’s Gazyva/Gazyvaro for treatment of lupus nephritis
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a CRR benefit in lupus nephritis